Noninvasive Prenatal Genetic Testing: Current and Emerging Ethical, Legal, and Social Issues
Tóm tắt
Noninvasive prenatal genetic testing (NIPT) for chromosomal aneuploidy involving the analysis of cell-free fetal DNA became commercially available in 2011. The low false-positive rate of NIPT, which reduces unnecessary prenatal invasive diagnostic procedures, has led to broad clinician and patient adoption. We discuss the ethical, legal, and social issues raised by rapid and global dissemination of NIPT. The number of women using NIPT is anticipated to expand, and the number of conditions being tested for will continue to increase as well, raising concerns about the routinization of testing and negative impacts on informed decision making. Ensuring that accurate and balanced information is available to all pregnant women and that access to NIPT is equitable will require policy guidance from regulators, professional societies, and payers. Empirical evidence about stakeholders' perspectives and experiences will continue to be essential in guiding policy development so that advances in NIPT can be used effectively and appropriately to improve prenatal care.
Từ khóa
Tài liệu tham khảo
5. Allyse M, Chandrasekharan S. 2015. Too much, too soon? Commercial provision of noninvasive prenatal screening for subchromosomal abnormalities and beyond.Genet. Med.In press. doi: 10.1038/gim.2015.23
11. Ariosa Diagn. 2015.FAQs for healthcare providers.http://www.ariosadx.com/healthcare-professionals/faqs
12. Asch A. 2000. Why I haven't changed my mind about prenatal diagnosis: reflections and refinements. See Ref. 148, pp. 234–58
Asch A, 2002, Fla. State Univ. Law Rev., 30, 315
Barot S, 2012, Guttmacher Policy Rev., 15, 18
27. BGI. 2014. BGI is granted patent in 16 countries for non-invasive prenatal genetic test technology.BGI News, Oct. 10.http://www.genomics.cn/en/news/show_news?nid=104192
28. BGI. 2014.FAQs.http://www.niftytest.com/healthcare-providers/faqs
29. BGI. 2014.Introduction to NIFTY™.http://www.niftytest.com/healthcare-providers/intro-to-nifty
39. Cent. Medicare Medicaid Serv. 2015.Pregnant women.http://www.medicaid.gov/medicaid-chip-program-information/by-population/pregnant-women/pregnant-women.html
42. Chen SJ. 2014. China cracks down on DNA testing.Forbes, Mar. 3.http://www.forbes.com/sites/shuchingjeanchen/2014/03/03/china-cracks-down-on-dna-testing-2
Dixon DP, 2008, Issues Law Med., 24, 3
55. Dondorp W, de Wert G, Bombard Y, Bianchi DW, Bergmann C, et al. 2015. Non-invasive prenatal testing for aneuploidy and beyond: challenges of responsible innovation in prenatal screening.Eur. J. Hum. Genet.In press. doi: 10.1038/ejhg.2015.57
Edwins J, 2000, Pract. Midwife, 3, 21
Faden RR, 1986, A History and Theory of Informed Consent
66. FDA (Food Drug Admin.). 2014.Draft guidance for industry, Food and Drug Administration staff, and clinical laboratories: framework for regulatory oversight of laboratory developed tests(LDTs). Guid. Doc. 1739, FDA, Silver Spring, MD.http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM416685.pdf
68. Finlay JE, Canning D, Po JY. 2012.Reproductive health laws around the world. Work. Pap. 96, Program Glob. Demogr. Aging, Harvard Univ.http://www.hsph.harvard.edu/program-on-the-global-demography-of-aging/WorkingPapers/2012/PGDA_WP_96.pdf
70. French HW. 2005. As girls “vanish,” Chinese city battles tide of abortions.New York Times, Feb. 17.http://www.nytimes.com/2005/02/17/international/asia/17china.html
71. GenomeWeb Staff Report. 2013. Shareholder sues Sequenom, alleging illegal “capping” of MaterniT21 Plus price to induce test adoption.GenomeWeb, Oct. 3.https://www.genomeweb.com/sequencing/shareholder-sues-sequenom-alleging-illegal-capping-maternit21-plus-price-induce
72. GenomeWeb Staff Report. 2014. BGI suspends clinical NGS-based trisomy testing in China.GenomeWeb, Mar. 14.https://www.genomeweb.com/sequencing/bgi-suspends-clinical-ngs-based-trisomy-testing-china
73. GenomeWeb Staff Report. 2014. China FDA approves BGI's NGS products.GenomeWeb, July 2.https://www.genomeweb.com/sequencing/china-fda-approves-bgis-ngs-products
74. GenomeWeb Staff Report. 2014. Illumina, Sequenom pool NIPT patents, settling IP disputes.GenomeWeb, Dec. 3.https://www.genomeweb.com/business-news/illumina-sequenom-pool-nipt-patents-settling-ip-disputes
75. GenomeWeb Staff Report. 2015. Berry Genomics lands China FDA approval for NIPT sequencer.GenomeWeb, Mar. 31.https://www.genomeweb.com/regulatory-news/berry-genomics-lands-china-fda-approval-nipt-sequencer
76. GenomeWeb Staff Report. 2015. Illumina sues Premaitha Health over NIPT IP; Swiss firm adopts Premaitha's Iona CE-IVD test.GenomeWeb, Mar. 16.https://www.genomeweb.com/business-news/illumina-sues-premaitha-health-over-nipt-ip-swiss-firm-adopts-premaithas-iona-ce-ivd
79. Green JM, Hewison J, Bekker HL, Bryant LD, Cuckle HS. 2004.Psychosocial aspects of genetic screening of pregnant women and newborns: a systematic review. Health Technol. Assess. 8(33), Natl. Inst. Health Res., Southampton, UK
91. Igenomix. 2015.NACE®:Non-Invasive Analysis for Chromosomal Examination.http://nace.igenomix.com/wp-content/uploads/NACE-specialists-EN.pdf
92. Illumina. 2015.Noninvasive prenatal testing—accurate information for your patients.http://www.illumina.com/clinical/reproductive-genetic-health/healthcare-professionals/non-invasive-prenatal-testing.html
93. Illumina. 2015.The reassurance of knowing.http://www.illumina.com/content/dam/illumina-marketing/documents/applications/reproductive-health/22336_LB_0013_G_Physician_Brochure.pdf
98. Kalantry S. 2014.Replacing myths with facts: sex-selective abortion laws in the United States. Cornell Leg. Stud. Res. Pap. 14-34, Cornell Law Sch., Ithaca, NY
100. Karow J. 2014. Premaitha to launch first CE IVD noninvasive prenatal test in Europe in early 2015.GenomeWeb, July 16.https://www.genomeweb.com/sequencing/premaitha-launch-first-ce-ivd-noninvasive-prenatal-test-europe-early-2015
101. Karow J. 2014. Sequenom to launch VisibiliT for average-risk pregnancies outside US, expand MaterniT21 Plus.GenomeWeb, July 23.https://www.genomeweb.com/sequencing/sequenom-launch-visibilit-average-risk-pregnancies-outside-us-expand-maternit21
106. Kittay EF, Kittay L. 2000. On the expressivity and ethics of selective abortion for disability: conversations with my son. See Ref. 148, pp. 165–95
Lampret JC, 2007, S. Afr. Med. J., 97, 515
115. LifeCodexx. 2014.PraenaTest®now starting at EUR 595.http://lifecodexx.com/wp-content/uploads/2015/03/WM-1097-EN-001_PraenaTest_is-now-starting_at_595EUR_Newsletter_July_2014_SCREEN.pdf
116. LifeCodexx. 2015.PrenaTest®.http://lifecodexx.com/en/expectant-mothers/prenatest
Lippman A, 1994, Women and Prenatal Testing: Facing the Challenges of Genetic Technology, 9
126. Maron DF. 2014. Virtual doctor visits gaining steam in “geneticist deserts.”Sci. Am., Apr. 21.http://www.scientificamerican.com/article/virtual-doctor-visits-gaining-steam
133. Minist. Health Fam. Welf. 2005.Annual report on implementation of the Pre-Conception and Pre-Natal Diagnostic Techniques(Prohibition of Sex Selection)Act.Rep., Minist. Health Fam. Welf., Gov. India, New Delhi
136. Natera. 2015.About Panorama™.http://www.panoramatest.com/healthcare-provider
137. Natera. 2015.FAQs.http://www.panoramatest.com/en/expecting-mother/faqs
138. Natl. Coalit. Health Prof. Educ. Genet. 2012.Non-invasive prenatal testing(NIPT)factsheet.http://www.nchpeg.org/index.php?option=com_content&view=article&id=384&Itemid=255
Parens E, 2000, Prenatal Testing and Disability Rights
151. Pinghui Z. 2014. Zhejiang man arrested for arranging sex tests in Hong Kong for pregnant mainland women.South China Morning Post, Apr. 18.http://www.scmp.com/news/china/article/1486420/zhejiang-man-arrested-arranging-sex-tests-hong-kong-pregnant-mainland
154. Pollack A. 2012. Conflict potential seen in genetic counselors.New York Times, July 13.http://www.nytimes.com/2012/07/14/business/conflict-potential-seen-in-genetic-counselors-paid-by-testing-companies.html
Rapp R, 1999, Testing Women, Testing the Fetus: The Social Impact of Amniocentesis in America
159. Ray. 2013. Amid “chaos,” FDA's Gutierrez offers insights on agency's regulatory stance on molecular tests.GenomeWeb, Feb. 12.https://www.genomeweb.com/clinical-genomics/amid-chaos-fdas-gutierrez-offers-insights-agencys-regulatory-stance-molecular-te
165. Saxton M. 2000. Why members of the disability community oppose prenatal diagnosis and selective abortion. See Ref. 148, pp. 147–64
169. Sequenom Lab. 2015.MaterniT21®PLUS.https://laboratories.sequenom.com/providers/maternit21-plus
170. Sequenom Lab. 2015.The science of revolutionizing prenatal care.http://flipbooks.sequenom.com/i/356741-mt21plus-microdeletions-essii-4-pg-brochure-070814-final-31-20241r1-0
171. Sequenom Lab. 2015.The VisibiliT™prenatal test.https://laboratories.sequenom.com/providers/visibilit
180. Soc. Matern.Fetal Med. 2014.SMFM statement: maternal serum cell-free DNA screening in low risk women.https://www.smfm.org/publications/157-smfm-statement-maternal-serum-cell-free-dna-screening-in-low-risk-women
183. Spec. Olymp. 2005.Changing attitudes changing the world: the health and health care of people with intellectual disabilities.Policy Pap., Spec. Olymp., Washington, DC
184. Steinbock B. 2000. Disability, prenatal testing, and selective abortion. See Ref. 148, pp. 108–23
189. Transpar. Mark. Res. 2014.Non-invasive prenatal testing(NIPT)market(MaterniT21 PLUS, verifi, Harmony, Panorama, NIFTY, PrenaTest and BambniTest)—global industry analysis, size, share, growth, trends and forecast, 2013–2019.Rep., Transpar. Mark. Res., Albany, NY
Van Zimmerman E, 2014, Breast Cancer Gene Research and Medical Practices: Transnational Perspectives in the Time of BRCA, 151
196. Wertz DC. 2000. Drawing lines: notes for policymakers. See Ref. 148, pp. 261–87
Willems PJ, 2014, Facts Views Vis. ObGyn, 6, 7